Orchestra BioMed Holdings (OBIO) Current Leases (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Current Leases of $785000.0 for Q1 2026, up 33.05% year-over-year from $590000.0 in Q1 2025, and up 4.53% quarter-over-quarter from $751000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Current Leases (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Current Leases for 5 consecutive years, with $785000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 33.05% year-over-year to $785000.0; the TTM figure through Mar 2026 stood at $785000.0 (up 33.05% YoY), while the FY2025 annual figure was $751000.0, up 36.55% from the prior year.
- Current Leases grew to $785000.0 in Q1 2026 per OBIO's latest filing, from $751000.0 in the prior quarter.
- Across five years, Current Leases topped out at $785000.0 in Q1 2026 and bottomed at $350000.0 in Q2 2024.
- Historically, Current Leases has averaged $625500.0 across 5 years, with a median of $672500.0 in 2023.
- Annual changes were most pronounced in 2024 — Current Leases tumbled 51.99% — and 2025, when it surged 83.43%.
- Orchestra BioMed Holdings' Current Leases stood at $697000.0 in 2022, then declined by 6.89% to $649000.0 in 2023, then declined by 15.25% to $550000.0 in 2024, then jumped by 36.55% to $751000.0 in 2025, then grew by 4.53% to $785000.0 in 2026.
- Business Quant data shows OBIO's Current Leases at $785000.0 in Q1 2026, $751000.0 in Q4 2025, and $696000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 808,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 808,000.00 |
| Mar 31, 2026 | 785,000.00 |
| Dec 31, 2025 | 751,000.00 |
| Sep 30, 2025 | 696,000.00 |
| Jun 30, 2025 | 642,000.00 |
| Mar 31, 2025 | 590,000.00 |
| Dec 31, 2024 | 550,000.00 |
| Sep 30, 2024 | 395,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 465,000.00 |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 747,000.00 |
| Jun 30, 2023 | 729,000.00 |
| Mar 31, 2023 | 711,000.00 |
| Dec 31, 2022 | 697,000.00 |